Skip to main content

Table 1 Demographic and clinical characteristics at screening (primary analysis set)

From: Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy

  Placebo-etanercept (N = 104) Etanercept-etanercept (N = 106) All patients (N = 210)
Age, mean years (SD) 55.5 (12.8) 56.5 (12.1) 56.0 (12.4)
Sex, n women (%) 86 (82.7) 75 (70.8) 161 (76.7)
Race, n (%)    
 White 90 (86.5) 91 (85.8) 181 (86.2)
 Black/African American 8 (7.7) 9 (8.5) 17 (8.1)
 Asian 3 (2.9) 2 (1.9) 5 (2.4)
 Other 3 (2.9) 4 (3.8) 7 (3.3)
BMI, mean kg/m2 (SD) 29.3 (6.6) 30.6 (7.7) 30.0 (7.2)
Duration of RA, mean years (SD) 7.4 (8.1) 8.3 (11.2) 7.8 (9.8)
DAS28-CRP, mean (SD) 4.9 (0.8) 4.9 (0.7) 4.9 (0.8)
  1. SD: standard deviation; BMI: body mass index; RA: rheumatoid arthritis; DAS28-CRP: Disease Activity Score based on 28 joints with C-reactive protein.